Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Breast and Gynecologic Cancer
National Cancer Institute (NCI)
Active, not recruiting ID
For more information, see NCT03036930
This phase II trial studies whether the nonavalent human papillomavirus vaccine given to adults prior to kidney transplantation can help the body build and maintain an effective immune response during the post-transplant period when they receive immunosuppressive drugs to prevent transplant rejection. This study will help inform our scientific understanding about vaccine-induced immune responses among immunosuppressed individuals.
Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine, Biospecimen Collection, HPV Self-Collection
Human Papillomavirus Infection
Marc T Goodman

See list of participating sites